TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04159103: A Global, Phase 1/2, Open-Label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3927 in Participants With Propionic Acidemia

Sponsor: ModernaTX, Inc. · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 77 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$338,640

Rescue Site Savings

+$225,760

Unlock Full NCT04159103 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04159103 Rescue Dossier →